Replies to post #227709 on Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

Thx for the response tryz,

I was just asking where the figure is noted. Is it in the 10q(Idid not see it), or was it an estimation on sox's part(he's probably watching the red sox-yankees game and not following the posts)? Even if they did raise $2M from 4/1/18 till today, just their operating expenses + rent per calender day is $27,236 based on todays 10q. Multiply that by 40 days= $1,089,440 gone. There are other expenses.

In response to:

"That's right learn the math with the additional 2 million raised between April to May 9th = 3.3 million......Gonna be some sort of excitement coming in the way of investors in the coming weeks....Boom time as taken from another poster here.....enjoy,tryz"

I do feel the same as you regarding the future, just wondering if I missed something in the 10q.

[loanranger]

You can't roll the cash balance forward based on the share sales for that subsequent period without reflecting the cash spent...an unknown. Saying that the Company had $3.3M in Cash on 5/9 assumes that nothing was spent from April 1 until that date.

[DaubersUP]

Total OS wen up about 10 million
Q2 - It was 145,688,782 (Jan 31st)
Q3 - It is 155,091,427 (May 6th)

****Note - 8 Million of those 9,402,645 were released into market starting April 1st**** "From April 1, 2018 to May 9, 2018, the Company has generated additional proceeds of approximately $2.0 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 8.0 million shares of its common stock"

So lets dive back from Feb - April and see the sells/buys - 4Kids!!! This is a job for you. :) Because in that time they only diluted 1.4 million

The short report did add about 2-300K in that period too.

Business Development Activities

The Company is engaged in discussions and negotiations regarding the out-licensing of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in one or more assets in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.

Recently, we released results from our completed Phase 2 Brilacidin study on Oral Mucositis. The results have attracted inquiries, additional confidential disclosure agreements, and discussions with pharmaceutical companies.

The Company believes that Brilacidin-OM, with its granted Fast Track FDA designation, occupies a lead position among OM drug candidates currently advancing in competitive clinical pipelines.

Even better - In the 2 quarter Q - we owed a CRO 2.7 MILLION and now we are down to 1 Million. SO our cash did go but atleast we know that 1.7 MILLION went to our Prurisol CRO and now we owe them the final 1 Million and have 3.3 million left. We have plenty to get to a deal IMO!!!!

HERE WE GO! DEAL TOMORROW - drop the hammer Leo!